Combination extends survival vs. standard first-line therapy for advanced lung cancer
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with amivantamab-vmjw (Rybrevant,
J&J says its lung cancer drug combination keeps people alive longer
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to supplant AstraZeneca's blockbuster Tagrisso,
Johnson & Johnson says its lung cancer drug significantly extended survival
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer patients.
J&J says cancer drug combination showed survival benefit over Tagrisso
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.
Drug extends survival in lung cancer patients: J&J
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.
Johnson & Johnson’s rybrevant plus lazcluze improve survival in lung cancer
Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from
Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study
Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.
Cure Today1d
Rybrevant Plus Lazcluze Improves Survival for EGFR+ NSCLC
First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...
FiercePharma3d
With key win over AstraZeneca's Tagrisso, J&J touts Rybrevant-Lazcluze combo as 'new standard of care'
Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
GlobalData on MSN2d
J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
PharmaTimes8d
EC approves Rybrevant with Lazcluze for advanced lung cancer
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...
Genmab’s Strategic Positioning and Promising Clinical Data Drive Buy Rating with $50 Price Target
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Genmab (GMAB – Research Report). The associated price target ...